Identification
- Brand Names
- EnBrace HR, EnLyte
- Generic Name
- Magnesium ascorbate
- DrugBank Accession Number
- DB14484
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Nutraceutical
- Structure
Structure for Magnesium ascorbate (DB14484)
- Weight
- Average: 374.537
Monoisotopic: 374.03356759 - Chemical Formula
- C12H14MgO12
- Synonyms
- Ascorbic acid, magnesium salt
- L(+)-ascorbic acid magnesium salt
- Vitamin C magnesium salt
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmphetamine The serum concentration of Amphetamine can be decreased when it is combined with Magnesium ascorbate. Benzphetamine The serum concentration of Benzphetamine can be decreased when it is combined with Magnesium ascorbate. Chlorpropamide Magnesium ascorbate may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. Dextroamphetamine The serum concentration of Dextroamphetamine can be decreased when it is combined with Magnesium ascorbate. Diethylpropion The serum concentration of Diethylpropion can be decreased when it is combined with Magnesium ascorbate. - Food Interactions
- Take with or without food. Taking magnesium supplements with food may reduce the risk of diarrhea.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Ascorbic acid unknown PQ6CK8PD0R 50-81-7 CIWBSHSKHKDKBQ-JLAZNSOCSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Energy 80 Prolonged Release Tab Magnesium ascorbate (410 mg / tab) + Calcium ascorbate (130 mg / tab) + Cyanocobalamin (100 mcg / tab) + Folic acid (25 mcg / tab) + Pantothenic acid (25 mg / tab) + Pyridoxine hydrochloride (25 mg / tab) Tablet, extended release Oral Sportscience Labs Inc. 1981-12-31 2002-06-20 Canada 
PramLyte Magnesium ascorbate (24 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Betaine (500 ug/1) + Citric acid monohydrate (1.83 mg/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Escitalopram oxalate (10 mg/1) + Ferrous cysteine glycinate (13.6 mg/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (7 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1) + Sodium citrate (3.67 mg/1) + Zinc ascorbate (1 mg/1) Kit Oral Allegis Pharmaceuticals, LLC 2015-09-11 2016-01-04 US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image EnBrace HR Magnesium ascorbate (24 mg/1) + 1,2-docosahexanoyl-sn-glycero-3-phosphoserine calcium (6.4 mg/1) + 1,2-icosapentoyl-sn-glycero-3-phosphoserine calcium (800 ug/1) + Betaine (500 ug/1) + Cobamamide (50 ug/1) + Cocarboxylase (25 ug/1) + Ferrous cysteine glycinate (13.6 mg/1) + Flavin adenine dinucleotide (25 ug/1) + Folic acid (1 mg/1) + Magnesium L-threonate (1 mg/1) + Leucovorin (2.5 mg/1) + Levomefolate magnesium (5.23 mg/1) + NADH (25 ug/1) + Phosphatidyl serine (12 mg/1) + Pyridoxal phosphate (25 ug/1) + Zinc ascorbate (1 mg/1) Capsule, delayed release pellets Oral Jaymac Pharma 2011-08-12 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0N1G678593
- CAS number
- 15431-40-0
- InChI Key
- AIOKQVJVNPDJKA-ZZMNMWMASA-L
- InChI
- InChI=1S/2C6H8O6.Mg/c2*7-1-2(8)5-3(9)4(10)6(11)12-5;/h2*2,5,7-10H,1H2;/q;;+2/p-2/t2*2-,5+;/m00./s1
- IUPAC Name
- magnesium(2+) bis((2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate)
- SMILES
- [Mg++].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO.[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO
References
- General References
- Not Available
- External Links
- ChemSpider
- 17339241
- Wikipedia
- Mineral_ascorbates
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Withdrawn Treatment Menstrual Related Mood Disorder / Premenstrual Dysphoric Disorder (PMDD) / Premenstrual Syndrome (PMS) / Premenstrual tension with edema 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, extended release Oral Capsule, liquid filled Oral Capsule, delayed release pellets Oral Tablet Oral Capsule Oral Kit Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 9.07 mg/mL ALOGPS logP -1.7 ALOGPS logP -1.9 Chemaxon logS -1.6 ALOGPS pKa (Strongest Acidic) 4.36 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 110.05 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 47.58 m3·mol-1 Chemaxon Polarizability 14.53 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 138.6376793 predictedDarkChem Lite v0.1.0 [M+H]+ 140.2096793 predictedDarkChem Lite v0.1.0 [M+Na]+ 138.8811793 predictedDarkChem Lite v0.1.0
Drug created at July 06, 2018 22:23 / Updated at June 12, 2020 16:53